Vir Historical Balance Sheet

About Vir Balance Sheet Analysis

Profit & Loss Statement Details

Cash Flow Statement Details

Financial Indicators Details

Valuation Indicators Details

Vir Biotechnology Balance Sheet Chart

At this time, Vir Biotechnology's Short Term Investments are relatively stable compared to the past year. As of 11/29/2024, Capital Surpluse is likely to grow to about 1.9 B, while Total Stockholder Equity is likely to drop slightly above 941.7 M.

Total Assets

Total assets refers to the total amount of Vir Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vir Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Vir Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vir Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Vir Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Vir Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Accumulated Depreciation

Accumulated depreciation is the total amount of depreciation for Vir Biotechnology fixed asset that has been charged to Vir Biotechnology expense since that asset was acquired and made available for Vir Biotechnology use. The accumulated depreciation account is Vir Biotechnology asset account with a credit balance. It is also known as a contra asset account and appears on the balance sheet as a reduction from the gross amount of fixed assets reported by Vir Biotechnology.

Vir Biotechnology balance sheet Correlations

Vir Biotechnology Account Relationship Matchups

Vir Biotechnology balance sheet Accounts

Pair Trading with Vir Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Additional Tools for Vir Stock Analysis